克服E3酶介导抵抗:开发基于标记的新型疏水性降解剂,向ALK蛋白
Shaowen Xie1, Jingjie Zhu1, Fangyi Zhan1
1Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, China.
Journal of medicinal chemistry
|July 24, 2025
概括
新的疏水标签 (HyTs) 通过绕过E3结合酶来降解形淋巴瘤激酶 (ALK). 这种新的方法克服了耐药性,显示了针对ALK的精密瘤治疗的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 针对向蛋白质降解 (TPD) 的传统蛋白质溶解向嵌合体 (PROTACs) 依赖于E3无素连接酶,对抗性机制提出了挑战.
- 无细胞淋巴瘤激酶 (ALK) 是某些癌症的关键点,但对现有疗法的耐药性是一个重要的临床问题.
研究的目的:
- 发现和描述针对ALK的向蛋白降解的新型疏水标签 (HyTs).
- 评估这些HyT在体外和体内疗效,特别是克服E3依赖联酶的耐药性.
主要方法:
- 基于norbornene和bornane的疏水标签 (HyTs) 的合成和评估.
- 在体外测试评估蛋白质降解和抗增殖活性.
- 在体内研究以确定瘤抑制和口服生物可用性.
- 对降解机制的研究,包括Hsp70的作用和无素-蛋白酶体通路.
主要成果:
- 基于诺伯的J26和基于博的J21在体外显示出显著的ALK降解和抗增殖作用.
- 即使减少了CRBN (一种E3酶) 表达,J26也有效降解了EML4-ALK.
- 在体内,J26抑制了瘤生长,并通过Hsp70伴侣系统和无素-蛋白酶体通路运作,独立于CRBN.
结论:
- 疏水标签 (HyTs) 提供了一种针对ALK的向蛋白质降解的新策略.
- J26的CRBN独立机制为ALK驱动的癌症中E3酶介导的耐药性提供了潜在的解决方案.
- 对于推进精密瘤治疗,HyT技术具有显著的前景.
相关概念视频
Regulated Protein Degradation
7.6K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.6K
Tagging and Fusion Proteins
6.9K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
6.9K
The Proteasome
1.2K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.2K


